Refreshing results…
The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma
UploadObinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA
UploadMissing publications? Search for publications with a matching author name.